227 related articles for article (PubMed ID: 32117721)
1. The Emerging Role of the c-MET-HGF Axis in Non-small Cell Lung Cancer Tumor Immunology and Immunotherapy.
Titmarsh HF; O'Connor R; Dhaliwal K; Akram AR
Front Oncol; 2020; 10():54. PubMed ID: 32117721
[TBL] [Abstract][Full Text] [Related]
2. Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.
Miranda O; Farooqui M; Siegfried JM
Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30134579
[TBL] [Abstract][Full Text] [Related]
3. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
[TBL] [Abstract][Full Text] [Related]
4. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients.
Masuya D; Huang C; Liu D; Nakashima T; Kameyama K; Haba R; Ueno M; Yokomise H
Br J Cancer; 2004 Apr; 90(8):1555-62. PubMed ID: 15083185
[TBL] [Abstract][Full Text] [Related]
5. Corrigendum: The Emerging Role of the c-MET-HGF Axis in Non-small Cell Lung Cancer Tumor Immunology and Immunotherapy.
Titmarsh HF; O'Connor R; Dhaliwal K; Akram AR
Front Oncol; 2020; 10():1516. PubMed ID: 32974185
[TBL] [Abstract][Full Text] [Related]
6. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
[TBL] [Abstract][Full Text] [Related]
7. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.
Navab R; Liu J; Seiden-Long I; Shih W; Li M; Bandarchi B; Chen Y; Lau D; Zu YF; Cescon D; Zhu CQ; Organ S; Ibrahimov E; Ohanessian D; Tsao MS
Neoplasia; 2009 Dec; 11(12):1292-300. PubMed ID: 20019837
[TBL] [Abstract][Full Text] [Related]
8. Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer.
Siegfried JM; Gubish CT; Rothstein ME; Queiroz de Oliveira PE; Stabile LP
Mol Pharmacol; 2007 Sep; 72(3):769-79. PubMed ID: 17550984
[TBL] [Abstract][Full Text] [Related]
9. Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival.
Qiao H; Hung W; Tremblay E; Wojcik J; Gui J; Ho J; Klassen J; Campling B; Elliott B
J Cell Biochem; 2002; 86(4):665-77. PubMed ID: 12210733
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte growth factor produced in lung fibroblasts enhances non-small cell lung cancer cell survival and tumor progression.
Kanaji N; Yokohira M; Nakano-Narusawa Y; Watanabe N; Imaida K; Kadowaki N; Bandoh S
Respir Res; 2017 Jun; 18(1):118. PubMed ID: 28619066
[TBL] [Abstract][Full Text] [Related]
11. The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.
Parikh RA; Wang P; Beumer JH; Chu E; Appleman LJ
Onco Targets Ther; 2014; 7():969-83. PubMed ID: 24959084
[TBL] [Abstract][Full Text] [Related]
12. Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer.
D'Arcangelo M; Cappuzzo F
Biologics; 2013; 7():61-8. PubMed ID: 23493885
[TBL] [Abstract][Full Text] [Related]
13. [c-Met signaling pathway participating in the gefitinib resistance of different gene types of non-small cell lung cancer cells induced by HGF in vitro].
Xuan X; An C; Zhou C
Zhongguo Fei Ai Za Zhi; 2013 Sep; 16(9):464-9. PubMed ID: 24034993
[TBL] [Abstract][Full Text] [Related]
14. The role of hepatocyte growth factor and its receptor c-met in interactions between lymphocytes and stromal cells in secondary human lymphoid organs.
Skibinski G; Skibinska A; James K
Immunology; 2001 Apr; 102(4):506-14. PubMed ID: 11328385
[TBL] [Abstract][Full Text] [Related]
15. Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened airway HGF.
Stabile LP; Rothstein ME; Gubish CT; Cunningham DE; Lee N; Siegfried JM
J Thorac Oncol; 2014 Sep; 9(9):1285-93. PubMed ID: 25057941
[TBL] [Abstract][Full Text] [Related]
16. Crosstalk Mechanisms Between HGF/c-Met Axis and ncRNAs in Malignancy.
Liu X; Sun R; Chen J; Liu L; Cui X; Shen S; Cui G; Ren Z; Yu Z
Front Cell Dev Biol; 2020; 8():23. PubMed ID: 32083078
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
18. c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma.
Tokunou M; Niki T; Eguchi K; Iba S; Tsuda H; Yamada T; Matsuno Y; Kondo H; Saitoh Y; Imamura H; Hirohashi S
Am J Pathol; 2001 Apr; 158(4):1451-63. PubMed ID: 11290563
[TBL] [Abstract][Full Text] [Related]
19. HGF/MET Regulated Epithelial-Mesenchymal Transitions And Metastasis By FOSL2 In Non-Small Cell Lung Cancer.
Yin J; Hu W; Fu W; Dai L; Jiang Z; Zhong S; Deng B; Zhao J
Onco Targets Ther; 2019; 12():9227-9237. PubMed ID: 31807006
[TBL] [Abstract][Full Text] [Related]
20. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy.
Jankowski K; Kucia M; Wysoczynski M; Reca R; Zhao D; Trzyna E; Trent J; Peiper S; Zembala M; Ratajczak J; Houghton P; Janowska-Wieczorek A; Ratajczak MZ
Cancer Res; 2003 Nov; 63(22):7926-35. PubMed ID: 14633723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
